Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pharma money on display for Dems
Big Pharma has ponied up big bucks to help finance the Democratic National Convention--and the companies have sent their CEOs to Denver to put their mouths where their money is.
The list of health-oriented sponsors reads like a roll call of drugmakers: Merck, Amgen, Pfizer, AstraZeneca, Novartis, Mylan, Abbott and Eli Lilly. Five of those companies--Pfizer, AstraZeneca, Lilly, Amgen and Merck--have put CEO power behind their cash. AstraZeneca and Lilly dispatched their CEOs--David Brennan (photo) and John Lechleiter (photo), respectively--to receptions and luncheons the companies sponsored. Pfizer's Jeff Kindler (photo) and Amgen's Kevin Sharer (photo) participated in a health roundtable. And at a PhRMA-sponsored brunch, Merck CEO Richard Clark (photo) and AstraZeneca's Brennan mingled with the invitation-only crowd.
And tonight, when Barack Obama accepts the Democratic nomination, Pfizer folks will be on hand in coveted skybox seats reserved for those donors who've given more than $1 million. Let's see who turns up for John McCain's Republican star turn next week.
- read the WSJ Health Blog post
- see the FDA Legislative Watch piece
- get the skybox article from the Dallas Morning News
Related Articles:
Pharma for Obama, but neither candidate loves pharma
Dems still in the pharma-contribution lead
Dems beat out Republicans for life sciences cash
Pharma backs Barack with money, votes
The 2008 Election: What does it mean for drugmakers?
Obama, McCain united against drug costs
Pharma backs Dems 51 to 49
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


